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BACKGROUND
The recurrence score based on the 21-gene breast cancer assay predicts chemother-
apy benefit if it is high and a low risk of recurrence in the absence of chemotherapy 
if it is low; however, there is uncertainty about the benefit of chemotherapy for most 
patients, who have a midrange score.
METHODS
We performed a prospective trial involving 10,273 women with hormone-recep-
tor–positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary 
node–negative breast cancer. Of the 9719 eligible patients with follow-up informa-
tion, 6711 (69%) had a midrange recurrence score of 11 to 25 and were randomly 
assigned to receive either chemoendocrine therapy or endocrine therapy alone. The 
trial was designed to show noninferiority of endocrine therapy alone for invasive 
disease–free survival (defined as freedom from invasive disease recurrence, second 
primary cancer, or death).
RESULTS
Endocrine therapy was noninferior to chemoendocrine therapy in the analysis of 
invasive disease–free survival (hazard ratio for invasive disease recurrence, second 
primary cancer, or death [endocrine vs. chemoendocrine therapy], 1.08; 95% con-
fidence interval, 0.94 to 1.24; P = 0.26). At 9 years, the two treatment groups had 
similar rates of invasive disease–free survival (83.3% in the endocrine-therapy group 
and 84.3% in the chemoendocrine-therapy group), freedom from disease recurrence 
at a distant site (94.5% and 95.0%) or at a distant or local–regional site (92.2% and 
92.9%), and overall survival (93.9% and 93.8%). The chemotherapy benefit for in-
vasive disease–free survival varied with the combination of recurrence score and 
age (P = 0.004), with some benefit of chemotherapy found in women 50 years of 
age or younger with a recurrence score of 16 to 25.
CONCLUSIONS
Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in 
women with hormone-receptor–positive, HER2-negative, axillary node–negative 
breast cancer who had a midrange 21-gene recurrence score, although some benefit 
of chemotherapy was found in some women 50 years of age or younger. (Funded 
by the National Cancer Institute and others; TAILORx ClinicalTrials.gov number, 
NCT00310180.)
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Breast cancer is the most common cancer in women in the United States and worldwide.1 Hormone-receptor–positive, ax-
illary node–negative disease accounts for approxi-
mately half of all cases of breast cancer in the 
United States.2 Adjuvant chemotherapy reduces 
the risk of recurrence,3-5 with effects that are pro-
portionally greater in younger women but that are 
little affected by nodal status, grade, or the use 
of adjuvant endocrine therapy.6,7 These findings 
led a National Institutes of Health consensus 
panel to recommend adjuvant chemotherapy for 
most patients,8 a practice that has contributed to 
declining breast cancer mortality.9 However, the 
majority of patients may receive chemotherapy un-
necessarily.
The 21-gene recurrence-score assay (Oncotype 
DX, Genomic Health) is one of several commer-
cially available gene-expression assays that provide 
prognostic information in hormone-receptor–pos-
itive breast cancer.10,11 The recurrence score based 
on the 21-gene assay ranges from 0 to 100 and is 
predictive of chemotherapy benefit when it is high, 
whether a high score is defined as 31 or higher12,13 
or 26 or higher12,14; when the recurrence score is 
low (0 to 10), it is prognostic for a very low rate of 
distant recurrence (2%) at 10 years that is not 
likely to be affected by adjuvant chemotherapy.12,14 
Although expert panels recommend the use of the 
21-gene assay,15,16 uncertainty remains as to wheth-
er chemotherapy is beneficial for the majority of 
patients, who have a mid-range recurrence score.
The Trial Assigning Individualized Options 
for Treatment (TAILORx) was designed to address 
these gaps in our knowledge by determining 
whether chemotherapy is beneficial for women 
with a mid-range recurrence score of 11 to 25. It 
was a prospective clinical trial, a type of trial that 
provides the highest level of evidence supporting 
the clinical usefulness of a biomarker.17 Another 
objective of the trial was to prospectively confirm 
that a low recurrence score of 0 to 10 is associated 
with a low rate of distant recurrence when patients 
are treated with endocrine therapy alone.18
Me thods
Trial Oversight
We conducted a prospective clinical trial sponsored 
by the National Cancer Institute that was coordi-
nated by the Eastern Cooperative Oncology Group 
(ECOG) and subsequently by the ECOG–Ameri-
can College of Radiology Imaging Network (ACRIN) 
Cancer Research Group, with other federally fund-
ed groups participating, including the Southwest 
Oncology Group, Alliance for Clinical Trials in 
Oncology, NRG Oncology, and Canadian Cancer 
Trials Group. Women who participated in the 
trial provided written informed consent, includ-
ing a statement of willingness to have treatment 
assigned or randomly assigned on the basis of 
the recurrence-score results. An Oncotype DX 
recurrence-score assay was performed in a cen-
tral laboratory (Genomic Health) on samples 
obtained from every woman who participated in 
the trial.10 Additional details are provided in the 
Supplementary Appendix and the protocol, both 
of which are available with the full text of this 
article at NEJM.org.
The authors performed the statistical analysis 
and wrote the first draft of the manuscript; the 
final submitted manuscript, which incorporated 
changes recommended by the coauthors and by 
Genomic Health, was reviewed and approved by 
all the authors, who vouch for the accuracy and 
completeness of the data and for adherence of 
the trial to the protocol. No one who is not an 
author contributed to the manuscript. Commer-
cial support was not provided for the planning and 
execution of the trial but was provided by Ge-
nomic Health for the collection of follow-up in-
formation from the treating sites.
Trial Population, Treatment, and End Points
We enrolled women who were 18 to 75 years of 
age; had hormone-receptor–positive, human epi-
dermal growth factor receptor 2 (HER2)–negative, 
axillary node–negative breast cancer; and met Na-
tional Comprehensive Cancer Network guidelines 
for the recommendation or consideration of ad-
juvant chemotherapy (the full list of inclusion 
and exclusion criteria is provided in the Supple-
mentary Appendix). On the basis of the 21-gene 
recurrence score, women were assigned to one of 
four treatment groups. Women with a recurrence 
score of 10 or lower were assigned to receive 
endocrine therapy only, and women with a score 
of 26 or higher were assigned to receive chemo-
therapy plus endocrine (chemoendocrine) therapy. 
Women with a midrange score of 11 to 25 under-
went randomization and were assigned to receive 
either endocrine therapy alone or chemoendocrine 
therapy. Additional details are provided in the 
Supplementary Appendix.
A Quick Take is 
available at 
NEJM.org 
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The standardized definitions for efficacy end 
points (STEEP) criteria were used for end-point 
definitions (Section 6B in the Supplementary 
Appendix).19 The primary end point was invasive 
disease–free survival, defined as freedom from 
invasive disease recurrence, second primary can-
cer, or death. Key secondary end points included 
freedom from recurrence of breast cancer at a 
distant site (which corresponds to the STEEP defi-
nition of distant recurrence–free interval), free-
dom from recurrence of breast cancer at a dis-
tant or local–regional site (which corresponds to 
the STEEP definition of recurrence-free interval), 
and overall survival. Full definitions of all the end 
points are provided in the Supplementary Ap-
pendix.
Statistical Analysis
The overall sample size was driven by the need 
to include a sufficient number of patients with a 
recurrence score of 11 to 25 to test the noninfe-
riority of endocrine therapy alone (the experimen-
tal group) to chemoendocrine therapy (the stan-
dard group) in this cohort of patients. Because 
of concern that nonadherence to the assigned 
treatment could make determination of an ap-
propriate noninferiority margin problematic, the 
test of noninferiority used a null hypothesis of 
no difference, as when testing for superiority, but 
with a larger type I error (one-sided 10%) and 
smaller type II error (5%) than usual. In this ap-
proach, controlling the type II error is critical, 
so failure to reject equality provides evidence for 
a conclusion of noninferiority. A 5-year rate of 
invasive disease–free survival of 90% with che-
moendocrine therapy and of 87% or less with 
endocrine therapy alone, which corresponds to a 
32.2% higher risk of an invasive disease recur-
rence, second primary cancer, or death as a result 
of not administering chemotherapy (hazard ratio, 
1.322), was prespecified as unacceptable.12,14
The primary analysis was a comparison ac-
cording to the assigned treatment. Because of a 
rate of nonadherence (12%) that was larger than 
had originally been projected (5%), the sample 
size of the group that underwent randomization 
(i.e., women with a recurrence score of 11 to 25) 
was increased by 73% (relative to a design with 
100% adherence, based on the Lachin–Foulkes 
correction),20 which resulted in a target sample size 
of 6517 eligible patients undergoing randomiza-
tion. The analysis was also performed according 
to the actual treatment given in order to explore 
the effect of nonadherence. The final analysis took 
place on March 2, 2018, at which time the pre-
specified number of events required for full in-
formation (835 events) had occurred. The analysis 
methods are further described in Section 6B in 
the Supplementary Appendix.
R esult s
Characteristics of the Patients
A total of 10,273 women were registered between 
April 7, 2006, and October 6, 2010, of whom 
10,253 were eligible for participation. Among the 
9719 eligible patients with follow-up information 
who were included in the main analysis set, 6711 
(69%) had a recurrence score of 11 to 25, 1619 
(17%) had a recurrence score of 10 or lower, and 
1389 (14%) had a recurrence score of 26 or high-
er (Fig. 1). The median duration of follow-up in 
the cohort of patients with a recurrence score of 
11 to 25 was 90 months for invasive disease–free 
survival and 96 months for overall survival. The 
characteristics of the trial population that was 
included in the main analysis are shown in Ta-
ble 1, and in Table S1 in the Supplementary Ap-
pendix.
Adjuvant Therapy in the Cohort  
with a Recurrence Score of 11 to 25
The median duration of endocrine therapy was 
5.4 years, with similar distributions of durations 
in the two randomly assigned treatment groups, 
including approximately 35% rates of adjuvant 
endocrine therapy extending beyond 5 years (Fig. 
S1 in the Supplementary Appendix). The most 
common chemotherapy regimens among the pa-
tients who were randomly assigned to and treated 
with chemotherapy were docetaxel–cyclophospha-
mide (56%) and anthracycline-containing regi-
mens (36%). The endocrine therapy regimens 
among postmenopausal women most commonly 
included an aromatase inhibitor (91%); among 
premenopausal women, endocrine therapy regi-
mens most commonly included either tamoxifen 
alone or tamoxifen followed by an aromatase 
inhibitor (78%), and suppression of ovarian func-
tion was used in 13% of premenopausal women 
(Table S2 in the Supplementary Appendix). The 
rate of nonadherence to the assigned treatment 
was 11.8% overall, including 5.4% among patients 
who were randomly assigned to receive endo-
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crine therapy alone and 18.4% among those 
who were randomly assigned to receive chemo-
endocrine therapy (Table 1). In the as-treated 
population, some of the differences in baseline 
characteristics between the treatment groups 
were significant (Table S3 in Supplementary Ap-
pendix).
Invasive Disease–free Survival  
and Other End Points in the Cohort  
with a Recurrence Score of 11 to 25
There had been 836 events of invasive disease 
recurrence, second primary cancer, or death (the 
components of invasive disease–free survival, 
the primary end point) in the two randomly as-
Figure 1. Registration, Randomization, and Follow-up.
All the patients who met the eligibility criteria and provided written informed consent were preregistered; a primary tumor specimen 
was subsequently obtained and sent to the Genomic Health laboratory for the 21-gene assay. On receipt of the assay report and recur-
rence-score result by the treating physician, the enrolling site then assigned patients to a treatment group. If the recurrence score was  
10 or lower, the patient was assigned to receive endocrine therapy alone. If the recurrence score was 26 or higher, the patient was as-
signed to receive chemoendocrine therapy. If the recurrence score was 11 to 25, the patient underwent randomization and was assigned 
to receive either endocrine therapy or chemoendocrine therapy. The stratification factors that were used in randomization were tumor 
size (≤2 cm vs. >2 cm), menopausal status (pre- vs. postmenopausal), planned chemotherapy (taxane-containing vs. not), planned radi-
ation therapy (whole breast and no boost irradiation planned vs. whole breast and boost irradiation planned vs. partial breast irradiation 
planned vs. no planned radiation therapy for patients who had undergone a mastectomy), and recurrence-score group (11 to 15 vs.  
16 to 20 vs. 21 to 25), which was added midway through the trial.
10,273 Registered and were assigned
to a treatment group
11,232 Patients were preregistered
959 Did not register
182 Were ineligible
551 Withdrew
33 Had medical reason
159 Had other reasons
34 Did not report a reason
1629 Had recurrence score ≤10
and were assigned to receive
endocrine therapy alone
10 Were excluded
3 Were ineligible
7 Did not have
trial-period infor-
mation, follow-
up information,
or either
1619 Were included in the main
analysis
56 Withdrew consent for
continued follow-up
93 Were lost to follow-up
3458 Had recurrence score 11–25
and were randomly assigned to
receive endocrine therapy alone
59 Were excluded
4 Were ineligible
55 Did not have
trial-period infor-
mation, follow-
up information,
or either
3399 Were included in the main
analysis
3214 Received assigned treat-
ment with endocrine
therapy only
185 Received adjuvant
chemotherapy
116 Withdrew consent for
continued follow-up
224 Were lost to follow-up
3449 Had recurrence score 11–25
and were randomly assigned to
receive chemoendocrine therapy
137 Were excluded
6 Were ineligible
131 Did not have
trial-period infor-
mation, follow-
up information,
or either
3312 Were included in the main
analysis
2704 Received assigned treat-
ment with adjuvant
chemotherapy
608 Did not receive chemo-
therapy
148 Withdrew consent for
continued follow-up
208 Were lost to follow-up
1737 Had recurrence score ≥26
and were assigned to receive
chemoendocrine therapy
348 Were excluded
7 Were ineligible
341 Did not have
trial-period infor-
mation, follow-
up information,
or either 
1389 Were included in the main
analysis
25 Withdrew consent for
continued follow-up
25 Were lost to follow-up
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Characteristic Recurrence Score of ≤10 Recurrence Score of 11–25 Recurrence Score of ≥26
Endocrine Therapy 
(N = 1619)
Endocrine Therapy 
(N = 3399)
Chemoendocrine 
 Therapy 
(N = 3312)
Chemoendocrine 
 Therapy 
(N = 1389)
Median age (range) — yr 58 (25–75) 55 (23–75) 55 (25–75) 56 (23–75)
Age ≤50 yr — no. (%) 429 (26) 1139 (34) 1077 (33) 409 (29)
Menopausal status — no. (%)†
Premenopausal 478 (30) 1212 (36) 1203 (36) 407 (29)
Postmenopausal 1141 (70) 2187 (64) 2109 (64) 982 (71)
Tumor size in the largest dimension — 
cm‡
Median (IQR) 1.5 (1.2–2.0) 1.5 (1.2–2.0) 1.5 (1.2–2.0) 1.7 (1.3–2.3)
Mean 1.74±0.76 1.71±0.81 1.71±0.77 1.88±0.99
Histologic grade of tumor — no./total 
no. (%)
Low 530/1572 (34) 959/3282 (29) 934/3216 (29) 89/1363 (7)
Intermediate 931/1572 (59) 1884/3282 (57) 1837/3216 (57) 590/1363 (43)
High 111/1572 (7) 439/3282 (13) 445/3216 (14) 681/1363 (50)
Estrogen-receptor expression — no. (%)
Negative 5 (<1) 6 (<1) 3 (<1) 40 (3)
Positive 1614 (>99) 3393 (>99) 3309 (>99) 1349 (97)
Progesterone-receptor expression — 
no./total no. (%)
Negative 28/1583 (2) 267/3339 (8) 251/3240 (8) 405/1353 (30)
Positive 1555/1583 (98) 3072/3339 (92) 2989/3240 (92) 948/1353 (70)
Clinical risk — no./total no. (%)§
Low 1227/1572 (78) 2440/3282 (74) 2359/3214 (73) 589/1359 (43)
High 345/1572 (22) 842/3282 (26) 855/3214 (27) 770/1359 (57)
Primary surgery — no. (%)
Mastectomy 516 (32) 935 (28) 917 (28) 368 (26)
Breast conservation 1103 (68) 2464 (72) 2395 (72) 1021 (74)
Adjuvant chemotherapy — no. (%)
Yes 8 (0.5) 185 (5.4) 2704 (81.6) 1300 (93.6)
No 1611 (99.5) 3214 (94.6) 608 (18.4) 89 (6.4)
*  Plus–minus values are means ±SD. The characteristics were well balanced between the two randomly assigned groups (i.e., the two groups 
with a recurrence score of 11 to 25) for all the factors listed. The differences between the group with a recurrence score of 10 or lower and 
the combined randomly assigned groups were significant for age, menopausal status, histologic grade, progesterone receptor status, and 
surgical procedure (P<0.001 for all comparisons). The differences between the group with a recurrence score of 26 or higher and the com-
bined randomly assigned groups were significant for the distributions of age (P = 0.003), menopausal status (P<0.001), tumor size 
(P<0.001), histologic grade (P<0.001), and progesterone receptor status (P<0.001).
†  Among the 14 patients for whom menopausal status was not reported, those who were 50 years of age or younger were classified as pre-
menopausal.
‡  There were 86 patients with a tumor size recorded as 0.5 cm or less and 20 patients with a tumor size greater than 5 cm. Information on tu-
mor size was missing for 2 patients with a recurrence score of 11 to 25 in the chemoendocrine-therapy group and for 1 patient with a recur-
rence score of 26 or higher.
§  Clinical risk was defined as in the MINDACT (Microarray in Node Negative Disease May Avoid Chemotherapy) trial (i.e., with low risk de-
fined as low histologic grade and tumor size ≤3 cm, intermediate histologic grade and tumor size ≤2 cm, or high histologic grade and tu-
mor size ≤1 cm; and with high risk defined as all other cases with known values for grade and tumor size).
Table 1. Characteristics of the Patients in the Intention-to-Treat Population at Baseline.*
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signed treatment groups at the time of the final 
analysis, including 338 (40.4%) recurrences of 
breast cancer as the first event, of which 199 
(23.8% of the total events) were distant recur-
rences (Tables S4 and S5 in the Supplementary 
Appendix). In the intention-to-treat population, 
endocrine therapy was noninferior to chemoen-
docrine therapy in the analysis of invasive dis-
ease–free survival (hazard ratio for invasive dis-
ease recurrence, second primary cancer, or death 
[endocrine vs. chemoendocrine therapy], 1.08; 
95% confidence interval [CI], 0.94 to 1.24; P = 0.26) 
(Fig. 2A). Endocrine therapy was likewise nonin-
ferior to chemoendocrine therapy in the analyses 
of other end points, including freedom from 
recurrence of breast cancer at a distant site (haz-
ard ratio for recurrence, 1.10; P = 0.48) (Fig. 2B), 
freedom from recurrence of breast cancer at a 
distant or local–regional site (hazard ratio for 
recurrence, 1.11; P = 0.33), and overall survival 
(hazard ratio for death, 0.99; P = 0.89). Additional 
details regarding these end points are provided 
in Figure S2 and Section 6B in the Supplemen-
tary Appendix.
The results of the as-treated analyses were 
consistent with those of the intention-to-treat 
analyses for invasive disease–free survival (haz-
ard ratio for invasive disease recurrence, second 
primary cancer, or death [endocrine vs. chemo-
endocrine therapy], 1.14; 95% CI, 0.99 to 1.31; 
P = 0.06), freedom from recurrence of breast 
cancer at a distant site (hazard ratio for recur-
rence, 1.03; P = 0.81), freedom from recurrence 
of breast cancer at a distant or local–regional 
site (hazard ratio for recurrence, 1.12; P = 0.28), 
and overall survival (hazard ratio for death, 0.97; 
P = 0.78) (Fig. S3 in the Supplementary Appendix). 
The estimated 9-year rates of invasive disease–
free survival in the as-treated population were 
83.1% for patients who received endocrine ther-
apy alone and 84.7% for those who received che-
moendocrine therapy. The outcomes were unlikely 
to have been affected by incomplete follow-up in-
formation (Section 6E in the Supplementary Ap-
pendix).
Survival Rates in All Recurrence-Score 
Cohorts and Treatment Groups
The estimated survival rates at 5 and 9 years for 
all treatment groups and end points are shown 
in Table 2. At 9 years in the intention-to-treat 
population, among patients with a recurrence 
score of 11 to 25, the rate of invasive disease–
free survival was 83.3% in the endocrine-therapy 
group and 84.3% in the chemoendocrine-therapy 
group; the corresponding rates were 94.5% and 
95.0% for freedom from recurrence of breast 
cancer at a distant site, 92.2% and 92.9% for 
freedom from recurrence of breast cancer at a 
distant or local–regional site, and 93.9% and 
93.8% for overall survival. When all recurrence-
score cohorts (≤10, 11 to 25, and ≥26) and treat-
ment-group assignments were considered, there 
were significant differences in the rates of inva-
sive disease–free survival, recurrence, and death 
(P<0.001), driven largely by the higher likelihood 
of having an event in the cohort with a recur-
rence score of 26 or higher (Fig. S4 in the Sup-
plementary Appendix). Distant recurrence was 
associated with recurrence score as a continuous 
variable between 11 and 25, but there was no sig-
nificant interaction between chemotherapy treat-
ment and recurrence score in this range (Figs. S5 
through S10 in the Supplementary Appendix).
Interactions According to Subgroup in the 
Cohorts with a Recurrence Score of 11 to 25
We performed exploratory analyses to determine 
whether any subgroups might have derived some 
benefit from chemotherapy in the intention-to-
treat population, with a focus on covariates that 
were prognostic or associated with greater benefit 
from chemotherapy, such as younger age (Section 
6F and Fig. S11 in the Supplementary Appendix).6 
There were no significant interactions between 
chemotherapy treatment and most of the prog-
nostic covariates examined, including recurrence-
score category (either 11 to 15 vs. 16 to 20 vs. 21 
to 25, or 11 to 17 vs. 18 to 25), tumor size (≤2 cm 
vs. >2 cm), histologic grade (low vs. intermediate 
vs. high), clinical risk category (high vs. low), and 
menopausal status (pre- vs. postmenopausal). 
There were significant interactions between che-
motherapy treatment and age (≤50 vs. 51 to 65 vs. 
>65 years) for invasive disease–free survival 
(P = 0.03) and for freedom from recurrence of 
breast cancer at a distant or local–regional site 
(P = 0.02) but not at a distant site (P = 0.12). The 
effect of treatment also varied significantly over 
the six combinations of menopausal status and 
recurrence-score category (11 to 15 vs. 15 to 20 
vs. 21 to 25) (P = 0.02) and over the nine combina-
tions of age and recurrence-score category 
(P = 0.004) for invasive disease–free survival (Figs. 
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S12 and S13 in the Supplementary Appendix) but 
not for freedom of recurrence of breast cancer at 
a distant site or distant or local–regional site. In 
women 50 years of age or younger, chemotherapy 
was associated with a lower rate of distant recur-
rence than endocrine therapy if the recurrence 
score was 16 to 20 (percentage-point difference, 
0.8 at 5 years and 1.6 at 9 years) or 21 to 25 (per-
centage-point difference, 3.2 at 5 years and 6.5 at 
9 years), although the rates of overall survival 
were similar (Table 3). Conversely, in the 40% of 
women 50 years of age or younger who had a re-
currence score of 0 to 15, the rate of distant re-
currence was approximately 2% at 9 years among 
those who had been assigned (either randomly or 
nonrandomly) to endocrine therapy alone.
Figure 2. Clinical Outcomes among Patients with a Recurrence Score of 11 to 25.
Kaplan–Meier estimates of survival rates in the analysis according to the assigned treatment group are shown for 
the group that received endocrine therapy alone and the group that received chemoendocrine therapy in the inten-
tion-to-treat analysis of invasive disease–free survival (defined as freedom from invasive disease recurrence, second 
primary cancer, or death) and freedom from recurrence of breast cancer at a distant site. The hazard ratios are for 
the endocrine-therapy group versus the chemoendocrine-therapy group.
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Discussion
In this prospective, randomized trial, we found 
that among 6711 women with hormone-receptor–
positive, HER2-negative, axillary node–negative 
breast cancer and a midrange recurrence score of 
11 to 25 on the 21-gene assay, endocrine therapy 
was not inferior to chemoendocrine therapy, which 
provides evidence that adjuvant chemotherapy 
was not beneficial in these patients. This find-
ing contrasts those of previous biomarker vali-
dation studies that were performed retrospec-
tively with the use of archival tumor specimens, 
in which a substantial benefit for the prevention 
of distant recurrence has been found for the com-
bination of chemotherapy and endocrine therapy 
in patients with a recurrence score of 26 or 
higher.12,13 The 9-year rate of distant recurrence 
in women with a recurrence score of 11 to 25 in 
our trial was approximately 5%, irrespective of 
chemotherapy use, a finding consistent with that 
predicted from the original report showing a sig-
nificant treatment interaction between chemo-
therapy benefit and a recurrence score of 26 or 
higher.14 Updated results for patients with a low 
recurrence score of 10 or less, who were previ-
ously reported as having a 1% distant recurrence 
rate at 5 years in our trial,18 now indicate a 9-year 
rate of distant recurrence of approximately 3%.
Population-based studies have shown a recur-
rence-score distribution similar to that observed 
in this prospective trial, along with no apparent 
benefit from chemotherapy in the recurrence-
score range of 11 to 25 and a significant asso-
ciation between recurrence score and recurrence 
or 5-year breast cancer–specific mortality, which 
indicates the generalizability of our findings to 
clinical practice.21,22 Although the rate of nonad-
herence to the assigned treatment was 12% over-
all, the sample size was adjusted to compensate 
for this, and the as-treated analysis produced re-
sults similar to those of the intention-to-treat 
analysis. The rate of nonadherence was similar 
to those in previous trials evaluating breast con-
servation or high-dose chemotherapy.23,24 Only 
24% of first events included in the primary end 
point (invasive disease recurrence, second pri-
mary cancer, or death) were distant recurrences, 
the type of recurrence that is most influenced by 
adjuvant chemotherapy,7 which also has some ef-
fect in reducing other events, such as local–regional 
recurrence or contralateral breast cancer.25,26
A total of 40% of women who were 50 years 
of age or younger had a recurrence score of 15 
or lower, which was associated with a low rate 
of recurrence with endocrine therapy alone. Ex-
ploratory analyses indicated that chemotherapy 
was associated with some benefit for women 50 
years of age or younger who had a recurrence 
score of 16 to 25 (a range of scores that was 
found in 46% of women in this age group). A 
greater treatment effect from adjuvant chemo-
therapy has been noted in younger women,7 
which may be at least partly explained by an 
antiestrogenic effect associated with premature 
menopause induced by chemotherapy.27 We did 
not collect data on chemotherapy-induced meno-
pause. It remains unclear whether similar bene-
fits could be achieved with ovarian suppression 
End Point and Treatment Group Rate at 5 Yr Rate at 9 Yr
percent
Invasive disease–free survival†
Score of ≤10, endocrine therapy 94.0±0.6 84.0±1.3
Score of 11–25, endocrine therapy 92.8±0.5 83.3±0.9
Score of 11–25, chemoendocrine therapy 93.1±0.5 84.3±0.8
Score of ≥26, chemoendocrine therapy 87.6±1.0 75.7±2.2
Freedom from recurrence of breast cancer  
at a distant site
Score of ≤10, endocrine therapy 99.3±0.2 96.8±0.7
Score of 11–25, endocrine therapy 98.0±0.3 94.5±0.5
Score of 11–25, chemoendocrine therapy 98.2±0.2 95.0±0.5
Score of ≥26, chemoendocrine therapy 93.0±0.8 86.8±1.7
Freedom from recurrence of breast cancer  
at a distant or local–regional site
Score of ≤10, endocrine therapy 98.8±0.3 95.0±0.8
Score of 11–25, endocrine therapy 96.9±0.3 92.2±0.6
Score of 11–25, chemoendocrine therapy 97.0±0.3 92.9±0.6
Score of ≥26, chemoendocrine therapy 91.0±0.8 84.8±1.7
Overall survival
Score of ≤10, endocrine therapy 98.0±0.4 93.7±0.8
Score of 11–25, endocrine therapy 98.0±0.2 93.9±0.5
Score of 11–25, chemoendocrine therapy 98.1±0.2 93.8±0.5
Score of ≥26, chemoendocrine therapy 95.9±0.6 89.3±1.4
*  Plus–minus values are Kaplan–Meier estimates ±SE.
†  Invasive disease–free survival was defined as freedom from invasive disease 
recurrence, second primary cancer, or death.
Table 2. Estimated Survival Rates According to Recurrence Score  
and Assigned Treatment in the Intention-to-Treat Population.*
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plus an aromatase inhibitor instead of chemo-
therapy.28,29
The MINDACT (Microarray in Node Negative 
Disease May Avoid Chemotherapy) trial was also 
a prospective trial integrating a gene-expression 
assay (with 70 genes) and randomized assign-
ment of chemotherapy.30 The primary end point 
in the trial focused on 644 patients with high 
clinical risk (48% node-positive, 8% HER2-posi-
tive) and low genomic risk who were assigned to 
receive no chemotherapy, and the prespecified 
prognostic end point of a 5-year rate of distant 
metastasis–free survival of more than 92% in 
this group of patients was met. Evidence-based 
guidelines recommend that the use of the assay 
be considered in cases of hormone-receptor–
positive, HER2-negative breast cancer and high 
clinical risk but not low clinical risk as defined 
in that trial.31 When the same clinical risk defi-
nitions were applied in our trial, 73.9% of the 
patients were at low clinical risk and 26.1% were 
at high clinical risk in the randomized treatment 
groups (Table 1), and we found no evidence sug-
gesting a chemotherapy benefit in either risk 
group.
On the basis of previous information regard-
ing the clinical validity and usefulness of the 
21-gene assay, the use of adjuvant chemotherapy 
has declined substantially in hormone-receptor–
positive, HER2-negative, axillary node–negative 
breast cancer.32 The results of our trial suggest 
that the 21-gene assay may identify up to 85% of 
women with early breast cancer who can be 
spared adjuvant chemotherapy, especially those 
who are older than 50 years of age and have a 
recurrence score of 25 or lower, as well as 
women 50 years of age or younger with a recur-
rence score of 15 or lower. Ongoing clinical tri-
als are obtaining additional information on the 
clinical usefulness of the 21-gene assay in 
women with hormone-receptor–positive breast 
cancer and positive axillary nodes33 and evaluat-
ing the clinical usefulness of the 50-gene assay 
in this context.34
The content of this article is solely the responsibility of the 
authors and does not necessarily represent the official views of 
the National Institutes of Health, nor does mention of trade 
names, commercial products, or organizations imply endorse-
ment by the United States government.
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CA180816, CA180821, CA180838, CA180822, CA180844, 
End Point and Treatment Group Rate at 5 Yr Rate at 9 Yr
percent
Invasive disease–free survival†
Score of ≤10, endocrine therapy 95.1±1.1 87.4±2.0
Score of 11–15, endocrine therapy 95.1±1.1 85.7±2.2
Score of 11–15, chemoendocrine therapy 94.3±1.3 89.2±1.9
Score of 16–20, endocrine therapy 92.0±1.3 80.6±2.5
Score of 16–20, chemoendocrine therapy 94.7±1.1 89.6±1.7
Score of 21–25, endocrine therapy 86.3±2.3 79.2±3.3
Score of 21–25, chemoendocrine therapy 92.1±1.8 85.5±3.0
Score of ≥26, chemoendocrine therapy 86.4±1.9 80.3±2.9
Freedom from recurrence of breast cancer at 
a distant site
Score of ≤10, endocrine therapy 99.7±0.3 98.5±0.8
Score of 11–15, endocrine therapy 98.8±0.6 97.2±1.0
Score of 11–15, chemoendocrine therapy 98.5±0.7 98.0±0.8
Score of 16–20, endocrine therapy 98.1±0.7 93.6±1.4
Score of 16–20, chemoendocrine therapy 98.9±0.5 95.2±1.3
Score of 21–25, endocrine therapy 93.2±1.7 86.9±2.9
Score of 21–25, chemoendocrine therapy 96.4±1.2 93.4±2.3
Score of ≥26, chemoendocrine therapy 91.1±1.6 88.7±2.1
Freedom from recurrence of breast cancer at 
a distant or local–regional site
Score of ≤10, endocrine therapy 98.4±0.6 95.4±1.3
Score of 11–15, endocrine therapy 97.5±0.8 93.3±1.6
Score of 11–15, chemoendocrine therapy 97.2±0.9 94.4±1.5
Score of 16–20, endocrine therapy 95.7±1.0 89.6±1.9
Score of 16–20, chemoendocrine therapy 97.2±0.8 93.0±1.5
Score of 21–25, endocrine therapy 89.8±2.0 82.0±3.2
Score of 21–25, chemoendocrine therapy 94.2±1.6 90.7±2.5
Score of ≥26, chemoendocrine therapy 88.6±1.8 86.1±2.2
Overall survival
Score of ≤10, endocrine therapy 100.0 98.6±0.9
Score of 11–15, endocrine therapy 99.3±0.4 96.8±1.0
Score of 11–15, chemoendocrine therapy 98.9±0.6 97.5±0.9
Score of 16–20, endocrine therapy 98.6±0.6 95.8±1.2
Score of 16–20, chemoendocrine therapy 99.8±0.2 96.1±1.2
Score of 21–25, endocrine therapy 98.2±0.9 92.7±2.0
Score of 21–25, chemoendocrine therapy 98.3±0.8 93.9±1.9
Score of ≥26, chemoendocrine therapy 95.6±1.1 92.4±1.9
*  Plus–minus values are Kaplan–Meier estimates ±SE.
†  Invasive disease–free survival was defined as freedom from invasive disease 
recurrence, second primary cancer, or death.
Table 3. Estimated Survival Rates According to Recurrence Score  
and Assigned Treatment among Women 50 Years of Age or Younger  
in the Intention-to-Treat Population.*
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